Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Haya Lorberboumgalski

Shai Yarkoni

Ala Fishman

The present invention generally relates to a new approach for the therapy of allergic responses, based on targeted elimination of cells expressing the Fc&#x3b5;RI receptor by a chimeric cytotoxin Fc-PE. A sequence encoding amino acids 301-437 of the Fc region of the mouse IgE molecule was genetically fused to PE&#x2014;a truncated form of PE lacking the cell binding domain. The chimeric protein, produced in, specifically and efficiently kills mouse mast cell lines expressing the Fc&#x3b5;RI receptor, as well as primary mast cells derived from bone marrow. The present invention provides a chimeric protein for targeted elimination of FcRI expressing cells especially useful for the therapy of allergic responses. The said chimeric protein is comprised of a cell targeting moiety for FcRI expressing cells and a cell killing moiety. The preferred killing moiety is the bacterial toxin Pseudomonas exotoxin (PE). This Pseudomonas exotoxin is a product of. The present invention also relates to a method for the preparation of said protein. This chimeric protein is prepared by genetically fusing the Fc region of the mouse IgE molecule to PE, a truncated form of PE lacking the cell binding domain. The present invention also provides pharmaceutical compositions, for the treatment of allergic diseases and for the treatment of hyperplasias and malignancies, comprising as an active ingredient the above mentioned chimeric protein and a conventional adjuvant product.

Fc&#x3b5;PE chimeric protein for targeted treatment of allergy responses, a method for its production and pharmaceutical compositions containing the same

Growing community of inventors

Jerusalem, Israel

Haya Lorberboumgalski